News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ferring Pharmaceuticals, Inc. Release: FIRMAGON® (degarelix) Demonstrates Non-inferiority to goserelin with bicalutamide in Reducing Prostate Volume in Prostate Cancer Patients while Providing Better Relief from Lower Urinary Tract Symptoms


2/28/2012 7:02:47 AM

PARIS--(BUSINESS WIRE)--Two new studies presented at the 27th Annual European Association of Urology (EAU) Congress reported that FIRMAGON® (degarelix), a gonadotropin-releasing hormone (GnRH) receptor blocker, was similar to the combination of goserelin (a luteinizing-hormone-releasing hormone (LHRH) agonist) plus bicalutamide at reducing total prostate volume in men with advanced hormone-dependent prostate cancer, and offered better control of lower urinary tract symptoms (LUTS).1,2 LUTS can include frequency, urgency and hesitancy in urination and have a major negative impact on quality of life3,4 for men with prostate cancer.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES